TB Is The #1 Killer Of People With HIV

People with HIV are 18 times more likely to develop active TB

Because people living with HIV have a weakened immune system, latent TB is more likely to develop into active TB. Active TB is deadlier for people with weakened immune systems.

HIV/AIDS contributes to 15% of all TB deaths worldwide

Fewer HIV infections means that

Fewer people with inactive TB will get sick with active TB, and
Fewer people with active TB will die of TB.

We Can Make Change!

2 Shots, 40 Dollars, Everywhere

Lenacapavir is a new injectable drug made by Gilead that is highly effective at both treating and preventing HIV.

Gilead recently struck a deal with The Global Fund to provide Lenacapavir for 3 million people by 2028. This deal is incredible, and it will save a lot of lives. But it also leaves out many lower- and middle-income countries where HIV is on the rise and tuberculosis is more prevalent.

To fill that gap, Doctors Without Borders (Médecins Sans Frontières/MSF) tried to buy Lenacapavir from Gilead directly, but Gilead refused.

We stand with MSF in calling for Gilead to make Lenacapavir available to all.